Information  X 
Enter a valid email address

Medical House PLC (MLH)

  Print      Mail a friend

Tuesday 08 September, 2009

Medical House PLC

US Patent for Autoinjector

RNS Number : 6590Y
Medical House PLC
08 September 2009
 



For Immediate Release

8 September 2009


The Medical House PLC


 US Patent Applications for ASITM Autoinjector Technology

Notices of Allowance


The Medical House PLC ('TMH' or the 'Company')(AIM:MLH), the drug delivery specialist, is pleased to announce that it has now received its first two Notices of Allowance from the US Patent and Trade Mark Office in respect of patents relating to its ASITM autoinjector device technology.


Ian Townsend, Chairman, The Medical House PLC, said: 

'These are extremely significant milestones for our company as successful US patent applications underpin our ability to out-license our ASITM autoinjector technology to our international client base. These patent approvals increase the likelihood of signing further licensing agreements for this key self-injection technology.'


On 12 August TMH announced that it had received an approach which may or may not lead to an offer for the Company. A further announcement will be made in due course.


Notes to Editors


Brief description of ASITM


The ASITM autoinjector technology enables patients to undertake a completely automated injection, including needle insertion and medication injection to needle withdrawal and safe retraction back into the device. When the injection is completed, the entire device unit is disposable. With an ASITM autoinjector device, patients never see or handle a needle, thereby reducing the anxiety that many people have about self-injection and eliminating the risk of accidental needlestick injuries. 


About The Medical House below provides greater details on its products and business.


Summary of ASITM  Commercialisation Agreements


TMH has signed licensing partnerships for the ASITM autoinjector platform with Dr. Reddy's Laboratories Ltd. (RDY-NYSE), Catalent Pharma Solutions, Inc. and Stallergenes SA (GENP-EPA), together with an undisclosed global pharmaceutical partner that licensed the ASITM autoinjector system . 


-Ends-


For further information:


The Medical House PLC

tel: 0114 261 9011

Ian Townsend, Chairman

www.themedicalhouse.com

Bryan Bodek Deputy Chairman




Buchanan Communications

Tel: 0207 466 5000

Tim Anderson / Stasa Filiplic




NomuraCode Securities

Richard Potts / Wolf Dornbusch

tel: 020 7776 1200



FinnCap


Stephen Norcross

Tel: 020 3207 3211

  


About The Medical House 


There is a growing trend in the pharmaceutical industry towards the use of disposable autoinjectors, incorporating pre-filled syringes, which facilitate patient self-injection, as a means of creating competitive advantage for injectable drugs, including a number of significant new biologic products. TMH's 'ASI' disposable autoinjector technology allows injections to be easily and safely undertaken by patients or by other non-clinicians such as family members and colleagues and are suitable for both elective therapies and emergency situations.  


In October 2008 TMH announced a non-exclusive development, licence and supply agreement with Catalent Pharma Solutions and Stallergenes to develop and distribute a variation of the company's core disposable autoinjector technology for use with epinephrine. Under the terms of this agreement, TMH will customise its proprietary, patented ASI disposable autoinjector device technology, according to an agreed specification and will be combined with epinephrine supplied by Catalent to create epinephrine autoinjectors for both adult and paediatric use.


These epinephrine autoinjectors are intended for the emergency treatment of anaphylactic shock, mostly due to hymenoptera venom or food allergies and for the use by patients themselves or by a person close to the patient in the event of an emergency. The newly-created product will be distributed exclusively by Stallergenes who are a European biopharmaceutical company, with annual sales in 2007 of €147 million, dedicated to desensitisation therapies for the prevention and treatment of allergy-related conditions. The Agreement covers 13 European countries, including the United Kingdom and incorporates provision for extension to additional territories.


In July 2008, TMH announced that it has signed a non-exclusive development, licensing and supply agreement with the global pharmaceutical company Dr Reddy's Laboratories ('Dr Reddy's'). Under the terms of the Agreement, TMH will customise its proprietary, patented ASI disposable autoinjector device technology, which will be combined by Dr Reddy's with an undisclosed drug, to create a new self-injectable product. The Agreement covers an initial 5 year term of supply, within USA, European Union and Canada, with an option for Dr Reddy's to extend the Agreement to the rest of the world, on mutually agreed terms. The duration of the Agreement may also be extended, again by mutual agreement. The development costs associated with customisation will be paid to TMH in addition to reimbursement of all agreed external costs. First commercial supply of the customised ASI device is expected to be in 2009-10 and TMH will receive a technology access fee during the term of the agreement. 


In November 2007, TMH announced that it has agreed to extend the term of the development, licensing and supply agreement for the ASI which it signed in December 2006 with a leading global pharmaceutical company. Under new terms, the minimum duration has been increased from five to six years, with TMH agreeing to a provision for further extension to approximately 16 years. TMH recently commenced work on the pre-commercial phase of the agreement's development programme In March 2008, TMH announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Compact AutoSafety Injector (CASI), which permits the placing of this device in the US market for assisting the self-administered subcutaneous injection of fixed doses of FDA-approved drug products presented in standard 1ml long pre-filled syringes with staked needles. The CASI is a version of TMH's ASI disposable autoinjector technology which is being developed for the global pharmaceutical company which extended their Agreement with TMH in November 2007. In May 2008, TMH announced that its global pharmaceutical partner had received regulatory approval in one of the principal territories to which the Agreement relates for a drug, a different formulation of which is in development for use with TMH's technology. 


Also in November 2007, TMH announced that it has signed a strategic marketing agreement with Catalent Pharma Solutions (formerly the Pharmaceutical Technologies and Services segment of Cardinal Health, Inc), a leading global provider of advanced technologies and outsourcing services to pharmaceutical and biotechnology companies. Under the terms of this agreement, the companies will jointly promote and market TMH's ASI system in combination with Catalent's services and technologies, which include sterile filling of pre-filled syringes. Catalent offers extensive capabilities for the development, manufacture and packaging of pharmaceutical and biotechnology products, and brings to the collaboration extensive customer relationships in nearly 100 countries, and an experienced business development team operating in the world's leading pharmaceutical markets. The companies are also exploring opportunities to jointly develop specific drug & device combination products, suitable for out-licensing and/or marketing partnerships with pharmaceutical industry partners.


Additional information is available at www.themedicalhouse.com



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSSAFIWSUSEIU

a d v e r t i s e m e n t